SCIENTIFIC BACKGROUND

AARS, ABCC9, ABCD1, ACSL4, ACTB, ACTG1, ADAT3, ADNP, AFF2, AHDC1, AIFM1, AKT3, ALDH5A1, ALG1, ALG11, ALG12, ALG13, ALG2, ALG3, ALG6, ALG8, ALG9, AMER1, AMPD2, ANK3, ANKLE2, ANKRD11, AP1S2, ARHGEF6, ARHGEF9, ARID1A, ARID1B, ARID2, ARX, ASH1L, ASPA, ASPM, ATP6AP2, ATP7A, ATRX, AUTS2, B4GALT1, BCAP31, BCOR, BCS1L, BDNF, BRAF, BRD4, BRWD3, C12orf4, C12orf57, CA8, CACNA1C, CACNG2, CAD, CAMK2A, CAMK2B, CAMK2G, CASK, CBL, CC2D1A, CCDC115, CCDC22, CCND2, CDK13, CDK5, CDK5RAP2, CDK6, CDKL5, CDKN1C, CENPE, CENPF, CENPJ, CEP135, CEP152, CEP85L, CHAMP1, CHD4, CHD7, CHD8, CHMP1A, CIC, CIT, CLCN4, CLIC2, CLN8, CLP1, CLTC, CNKSR2, CNOT3, CNTNAP2, COASY, COG1, COG4, COG5, COG6, COG7, COG8, COL4A1, COL4A2, COL4A3BP, COLGALT1, COPB2, CRADD, CRBN, CREBBP, CSNK2A1, CTCF, CTNNB1, CUL4B, DBH, DCX, DDC, DDOST, DDX3X, DEAF1, DHCR24, DHCR7, DIS3L2, DKC1, DLG3, DLG4, DNAJC12, DNM1, DNMT3A, DOCK7, DOLK, DONSON, DPAGT1, DPF2, DPM1, DPM2, DPM3, DVL1, DVL3, DYNC1H1, DYRK1A, EBP, EDC3, EED, EEF1A2, EHMT1, EIF2B5, EIF2S3, EIF3F, ELP2, EP300, EPB41L1, EXOSC3, EXOSC8, EXOSC9, EZH2, FANCB, FBXO31, FGD1, FLNA, FMN2, FMR1, FOXG1, FOXP1, FOXP2, FRMPD4, FTSJ1, GABRA1, GALT, GATAD2B, GCDH, GCH1, GDI1, GFAP, GK, GLI3, GNAI1, GNAO1, GNB1, GPAA1, GPC3, GPSM2, GRIA3, GRIK2, GRIN1, GRIN2A, GRIN2B, HCCS, HCFC1, HCN1, HDAC4, HDAC6, HDAC8, HEPACAM, HERC1, HIST1H1E, HIVEP2, HMGB3, HNRNPH2, HPRT1, HRAS, HSD17B10, HUWE1, IDS, IGBP1, IL1RAPL1, IMPA1, IQSEC2, ITPA, KANSL1, KAT6A, KAT6B, KATNB1, KCNA2, KCNB1, KCNQ2, KCNQ3, KCNQ5, KCNT1, KDM5C, KDM6A, KIF11, KIF14, KIF1A, KIF4A, KIF7, KIRREL3, KLHL15, KLHL7, KMT2A, KMT2D, KMT2E, KMT5B, KNL1, KPTN, KRAS, L1CAM, LAMB1, LAMP2, LAS1L, LINGO1, LINS1, LMNB1, LMNB2, LZTR1, MACF1, MAGT1, MAN1B1, MAOA, MAP11, MAP2K2, MBD5, MBOAT7, MBTPS2, MCPH1, MECP2, MED12, MED13, MED13L, MED23, MEF2C, METTL23, METTL5, MFSD2A, MGAT2, MICU1, MID1, MID2, MLC1, MOGS, MPDU1, MPI, MRAS, MSL3, MTM1, MTOR, MYT1L, NAA10, NAA15, NALCN, NCAPD2, NCAPD3, NCAPH, NDE1, NDP, NDST1, NDUFA1, NEXMIF, NFIB, NFIX, NGLY1, NHS, NIPBL, NLGN3, NLGN4X, NONO, NRAS, NRXN1, NSD1, NSDHL, NSUN2, NTNG1, NUP37, NUS1, NXF5, NXN, OCRL, OFD1, OGT, OPHN1, OTC, PACS1, PAFAH1B1, PAK3, PCBD1, PCDH11X, PCDH19, PCNT, PDHA1, PGAP1, PGAP2, PGAP3, PGK1, PGM1, PHC1, PHF6, PHF8, PIGA, PIGB, PIGC, PIGG, PIGH, PIGL, PIGM, PIGN, PIGO, PIGP, PIGQ, PIGS, PIGT, PIGU, PIGV, PIGW, PIGY, PIK3R2, PLP1, PMM2, PNKP, POGZ, PORCN, PPP1CB, PPP2CA, PPP2R1A, PPP2R5D, PPT1, PQBP1, PRPS1, PRSS12, PTCH1, PTCH2, PTCHD1, PTEN, PTPN11, PTS, PURA, PUS3, QDPR, RAB39B, RAB40AL, RAC1, RAD21, RAF1, RAI1, RARS2, RASA2, RBM10, RBMX, RELN, RFT1, RHEB, RIT1, RLIM, RNF113A, RNF135, ROR2, RPL10, RPL11, RPL15, RPL18, RPL26, RPL27, RPL35, RPL35A, RPL5, RPS10, RPS15A, RPS17, RPS19, RPS24, RPS26, RPS27, RPS28, RPS29, RPS6KA3, RPS7, RRAS, RUSC2, SASS6, SATB2, SCN1A, SCN2A, SCN8A, SCN9A, SEPSECS, SET, SETBP1, SETD2, SETD5, SHANK2, SHANK3, SHOC2, SIK1, SLC12A5, SLC13A5, SLC16A2, SLC18A2, SLC25A22, SLC25A46, SLC25A5, SLC35A1, SLC35A2, SLC35C1, SLC39A8, SLC6A17, SLC6A3, SLC6A8, SLC9A6, SMARCA2, SMARCA4, SMARCB1, SMARCC2, SMARCD1, SMARCE1, SMC1A, SMC3, SMPD4, SMS, SNX14, SON, SOS1, SOS2, SOX11, SOX3, SOX4, SOX5, SPR, SPTAN1, SRCAP, SRD5A3, SSR4, ST3GAL3, STAG1, STAG2, STIL, STT3A, STT3B, STXBP1, SUFU, SYN1, SYNGAP1, SYP, SZT2, TAF1, TAF13, TAF2, TBC1D23, TBC1D24, TBC1D7, TBCD, TBCK, TBL1XR1, TBR1, TCF4, TECR, TH, THOC2, TIMM8A, TLK2, TMCO1, TMEM165, TMEM199, TMLHE, TMTC3, TNIK, TOE1, TPH2, TRAPPC9, TRIO, TRIP12, TRMT1, TRRAP, TSC1, TSC2, TSEN15, TSEN2, TSEN34, TSEN54, TSPAN7, TSR2, TTI2, TUBA1A, TUBA8, TUBB, TUBB2A, TUBB2B, TUBB3, TUBG1, TUSC3, UBE2A, UBE3A, UPF3B, USP27X, USP9X, VPS13B, VPS51, VPS53, VRK1, WAC, WASHC4, WASHC5, WDFY3, WDR45, WDR62, WNT5A, WWOX, ZBTB11, ZBTB18, ZC3H14, ZC4H2, ZCCHC12, ZDHHC15, ZDHHC9, ZEB2, ZMYM3, ZMYND11, ZNF335, ZNF41, ZNF674, ZNF711, ZNF81

Scientific Background

Intellectual disability, defined as an IQ below 70, has a prevalence of 1.5 to 2%. Severe forms with an IQ of <50 have a prevalence of 0.3 to 0.4%. Males are more frequently affected due to X-linked genes. The causes of a reduction in intelligence are manifold; genetic factors, however, are involved in at least 50% of cases. With the examinations that have been possible so far, such as chromosome analysis, array CGH and targeted diagnostics (e.g., fragile X syndrome, Rett syndrome, Angelman syndrome), about 60% of the causes of developmental disorders remain unexplained. Several studies in recent years in which patients with severe intelligence impairment (IQ <50) were examined using new high-throughput sequencing (NGS) could confirm that dominant pathogenic de novo variants appear to contribute to a significant extent to the cause of severe intelligence impairment (e.g., Vissers L. et al, Nat Genet, 2010, de Ligt, J. et al, NEJM, 2012 and Rauch, A. et al, Lancet, 2012). According to these studies, it is assumed that up to about 30% of severe, non-syndromic developmental disorders are caused by de novo point mutations and small indels, with a large amount of genetic heterogeneity observed. In addition, autosomal recessive mutations also play a role in developmental disorders (approximately 13-24%), as well as mutations in X chromosomal genes (5-10% of male sufferers). As a further diagnostic tool, there is the possibility of using Next Generation Sequencing (NGS) for the simultaneous analysis of numerous genes related to neurological or developmental disorders that are already listed in databases.

 

In a number of developmental disorders, other symptoms are also at the forefront, such as autism spectrum disorders or conspicuous growth parameters, e.g., macrocephaly, microcephaly or macrosomia. In addition, there are syndromic forms of developmental disorders for which further syndromes and thus further pathological genes come into question for differential diagnosis (e.g., Rett and Rett-like syndromes). Finally, some better known, genetically heterogeneous syndromes can be effectively investigated by means of NGS (Cornelia de Lange syndrome, RASopathies, among others).

 

Alternatively, advanced diagnostics using clinical or whole exome analysis (CES/WES) is also possible.

 

References

Mir et Kuchay 2019, J of Med Genet doi: 10.1136/jmedgenet-2018-105821 / Jamra 2018, Med Genet 30:323 / Hu et al. 2018 Mol Psych doi.org/10.1038/s41380-017-0012-2 / Vissers et al 2016 Nat Rev Genet 17:9 / Tzschach et al 2015 Eur J of Hum Genet 23:1513 / Tan et al 2015 Clin Genet. doi: 10.1111 / cge.12575 / Musante et al 2014 Trends Genet 30:32 / Brett et al 2014 PLoS One 9(4): e93409 / Redin et al 2014 J Med Genet. 2014 51:724

 

 

INTELLECTUAL DISABILITY

Intellectual disability, defined as an IQ of less than 70, has a prevalence of 1.5% to 2%; earlier data reported 2% to 3%. More severe forms with an IQ <50 have a prevalence of 0.3% to 0.4%. Males are more commonly affected due to X-linked genes. The causes of intellectual disability are diverse; however, genetic factors are involved in at least 50% of cases. Comorbidities such as behavioral disorders and/or epilepsies are common. An accurate diagnosis is crucial for the patients and their families. Knowing the cause of the disability usually allows estimation of a prognosis, initiation of individual support measures if necessary, avoidance of further costly diagnostic measures, and statements about a possible risk of recurrence. If the cause of an intellectual disability is not clear, an empirical risk of recurrence of approximately 8% must be assumed for further pregnancies. Despite increasing numbers of new genetic syndromes associated with intellectual disability in recent years, the cause of intellectual disability still remains unexplained in some of patients.

 

In syndromic forms of intellectual disability, a characteristic combination of malformations, minor external abnormalities or characteristic behaviors may suggest a tentative diagnosis, which can be clarified with targeted diagnostics (e.g., fragile X syndrome, Rett syndrome, Angelman syndrome). However, many patients present with non-characteristic symptoms making the diagnosis impossible even for an experienced pediatrician or clinical geneticist. In this situation, the diagnostic approach to suspected genetic causes was global, i.e., the entire genome of the patient was investigated; however, the resolution increased over time, allowing a multitude of “new” causes to be identified. In the early days – and continuing to date – the examination starts with a chromosomal analysis, which can detect abnormal distributions of whole chromosomes, e.g., trisomies, or of smaller chromosomal parts, e.g., partial trisomies. Approximately 15% of developmental disorders are caused by chromosomal abnormalities that can be identified by light microscopy. However, even with a high resolution of 550 to 600 bands per haploid chromosome set, which can be achieved in routine diagnostics, changes that fall below 5-10 Mb cannot be detected. Therefore, a high-resolution chromosomal analysis using chromosomal microarray (CMA) is performed as a second diagnostic step. Large studies have shown that so-called copy number variations (CNVs), i.e., submicroscopic small deletions or duplications, are responsible for approximately 10 to 15% of cases of intellectual disability with inconspicuous chromosomal analysis. It has been shown that such CNVs are also frequently found in autism spectrum disorders, which occur both in isolation and in combination with a developmental disorder.

 

Even with these investigations, about 60% of the causes of developmental disorders remain unexplained. Since developmental disorders often occur sporadically, i.e., as an isolated case within a family, it has been assumed that new mutations occur, for example, in genes that are important for the development and interconnection of neurons, especially since humans have a high rate of new mutations.

 

Indeed, in recent years, several studies investigating patients with intellectual disability using new high-throughput techniques such as exome sequencing have confirmed that dominant new mutations seem to contribute to a large extent to the cause of severe (IQ < 50) intellectual disability. While the risk of chromosomal trisomies increases with maternal age, the rate of dominant new mutations increases with paternal age. Among the patients examined, variants were found in several genes. However, the causative mutation was in a gene already described in connection with developmental disorders in 16% of the patients in the study by de Ligt et al and in 35% of the patients in the study by Rauch et al. Based on these studies, it is thought that up to 50% of severe non-syndromic developmental disorders are caused by de novo point mutations and small indels with a large degree of genetic heterogeneity. Mutations in unknown genes or genes not known to be associated with developmental disorders require immense effort, including functional testing, to prove causal association. Nevertheless, exome sequencing is increasingly used in routine diagnostics, predominantly as a trio analysis, while genome sequencing is still largely limited to research. It is expected that using next generation sequencing (NGS) the underlying cause of approximately 30% of previously unexplained severe developmental disorders can be determined.

 

Currently, the diagnosis of a non-syndromic developmental disorder is made using a stepwise diagnostic approach starting with chromosomal analysis. If the findings are normal, a CMA is performed. If necessary, a molecular genetic examination can be conducted, e.g., to exclude fragile X syndrome or Angelman syndrome.

 

References

Harripaul et al. 2017, Cold Spring Harb Perspect Med 7:a026864 / Vissers et al. 2016, Nat Rev Genet 17:9 / Gillissen et al. 2014, Nature 511:344 / Musante et al. 2014, Trends in Genetics 30(1):32 / de Ligt et al. 2012, NEJM 367:1921 / Rauch et al. 2012, Lancet 380:1674 / Sharp 2011, Genet Med 13:191 / Cooper et al. 2011, Nat Genet 43:838 / Topper et al. 2011, Clin Genet 80:117 / Vissers et al. 2010, Nat Genet 42:1109 / Heinrich et al. 2009, J Lab Med 33:255 / Fan et al. 2007, Hum Mutat 28:1124 / Rauch et al. 2006, Am J Med Genet 140A:2063 / Rost and Klein 2005, J Lab Med 29:152 / Inlow and Restifo 2004, Genetics 166:235 / Battaglia and Carey 2003, Am J Med Genet 117C:3 / Leonhard et al. 2002, Ment Retard Dev Disabil Res Rev 8:117, 2002 / Curry et al. 1997, Am J Med Genet 72:46

 

 

FRAGILE X SYNDROME

Fragile X syndrome is the most common monogenic inherited cause of intellectual disability. In contrast to other diseases with X-linked recessive inheritance, fragile X syndrome shows healthy male carriers and in some of the female patients symptoms are as severe as in males. The incidence of affected males is estimated to be 1:5164 according to a 2009 study.

 

The cause of fragile X syndrome is a CGG triplet repeat expansion in the non-translated 5′ region of the FMR1 gene on the long arm of the X chromosome. The most common normal alleles in the general population have a length of 29-30 CGG repeats. Alleles in the range of 45 to 54 repeats are defined as gray zone alleles (EMQN ring trials). Some instability is already present at this repeat count, regardless of the sex of the carrier; however, expansion to a full mutation in one generation has not yet been observed in this range.

 

Alleles with 55 to 200 CGG repeats are referred to as premutation. In females, inheritance of premutations is unstable, usually leading to an extension of more than 200 triplets (full mutation) when they are passed on to the next generation. Above this length, methylation of cytosine residues of the repeat and adjacent regulatory elements occurs, ultimately leading to inhibition of transcription and consequent failure of the FMR1 gene product. In males, the premutation is stable when passed on to the next generation. Mothers of children with a full mutation are obligate carriers with either a premutation or a full mutation. The risk of recurrence is up to 50% for affected children depending on the sex or the length of the premutation in the mother.

 

In the presence of the full mutation, the developmental delay is first noticeable in childhood and usually affects speech more than motor skills. The children often have slightly abnormal measurements for body length and head circumference. Occasionally, symptoms of connective tissue weakness such as hyperextensible joints and muscle hypotonia are present. Hyperactivity and autistic behaviors are characteristic features. Apart from rather large ears, other phenotype features such as an elongated face and prominent chin are not very pronounced in childhood, but characterize adults with fragile X syndrome. Postpubertal macroorchidism is often seen in males. Female carriers of the full mutation can show variable symptoms ranging from an inconspicuous phenotype (about 30%) to intellectual disability of a severity similar to that seen in males. About 20% of premutation carriers have premature menopause (FXPOI). In older premutation carriers, particularly males, more than 30% show a progressive neurological disease pattern consisting of intention tremor, gait ataxia, parkinsonism, autonomic dysfunction and dementia, which is called fragile X tremor ataxia syndrome (FXTAS).

 

References

Mila et al. 2018, Clin Genet 93:197 / Hall et al. 2018, Handb Clin Neurol 147:377 / Hagermann et al. 2017, Nat Rev Dis Primers 3:17065 / Pugin et al. 2017, Neurologia 32:241 / Biancalana et al. 2015, Eur J Hum Genet 23:417 / Spath et al. 2010, Am J Med Genet A 152A:387 / Leitlinien zur molekulargenetischen Diagnostik: Fragiles-X und Fragiles-X assoziiertes Tremor/Ataxie Syndrom 2009, medgen 21 / Rost et Klein 2005, J Lab Med 29:152 / Nolin et al. 2003, Am J Hum Genet 72:454 / Oostra et al. 2001, Clin Genet 60:399 / Oostra et al. 1993, J Med Genet 30:410

 

 

LUJAN-FRYNS SYNDROME

Patients with Lujan-Fryns syndrome (LFS), also known as X-linked intellectual disability (XLMR) with marfanoid habitus or X-lined syndromic intellectual developmental disorder (MRXSLF), present with marfanoid habitus, certain craniofacial features, generalized muscle hypotonia, developmental delay, behavioral problems, and nasal speech. Thus, there is clinical overlap with other connective tissue disorders such as Marfan syndrome (MFS), Loeys-Dietz syndrome (LDS), and Shprintzen-Goldberg syndrome (SGS). Inheritance is X-linked recessive, resulting in predominantly male patients, while female carriers are usually clinically inconspicuous.

 

Hemizygous variants in the MED12 gene, which encodes mediator complex subunit 12, are the genetic cause. Allelic disorders with MED12 variants include FG syndrome type 1 (FGS1) and X‑linked Ohdo syndrome (XLOS). Subsequently, variants in the UPF3B and ZDHHC9 genes have also been described in patients with intellectual disability and marfanoid habitus. However, these patients only partially exhibited the characteristic facial abnormalities of LFS, such as a long narrow face, prominent forehead, broad nasal root, short philtrum, micrognathia, and high palate.

 

References

Charzewska et al. 2018, Clin Genet 94:450 / Hackmann et al. 2016, Am J Med Genet 170A:94 / Lyons. 2008 Jun 23 [Updated 2016 Aug 11]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. / Callier et al. 2013, Clin Genet 84:507 / Schwartz et al. 2007, J Med Genet 44:472 / Tarpey et al. 2007, Nat Genet 39:1127 / Raymond et al. 2007, Am J Hum Genet 80:982

 

GENES

AARS, ABCC9, ABCD1, ACSL4, ACTB, ACTG1, ADAT3, ADNP, AFF2, AHDC1, AIFM1, AKT3, ALDH5A1, ALG1, ALG11, ALG12, ALG13, ALG2, ALG3, ALG6, ALG8, ALG9, AMER1, AMPD2, ANK3, ANKLE2, ANKRD11, AP1S2, ARHGEF6, ARHGEF9, ARID1A, ARID1B, ARID2, ARX, ASH1L, ASPA, ASPM, ATP6AP2, ATP7A, ATRX, AUTS2, B4GALT1, BCAP31, BCOR, BCS1L, BDNF, BRAF, BRD4, BRWD3, C12orf4, C12orf57, CA8, CACNA1C, CACNG2, CAD, CAMK2A, CAMK2B, CAMK2G, CASK, CBL, CC2D1A, CCDC115, CCDC22, CCND2, CDK13, CDK5, CDK5RAP2, CDK6, CDKL5, CDKN1C, CENPE, CENPF, CENPJ, CEP135, CEP152, CEP85L, CHAMP1, CHD4, CHD7, CHD8, CHMP1A, CIC, CIT, CLCN4, CLIC2, CLN8, CLP1, CLTC, CNKSR2, CNOT3, CNTNAP2, COASY, COG1, COG4, COG5, COG6, COG7, COG8, COL4A1, COL4A2, COL4A3BP, COLGALT1, COPB2, CRADD, CRBN, CREBBP, CSNK2A1, CTCF, CTNNB1, CUL4B, DBH, DCX, DDC, DDOST, DDX3X, DEAF1, DHCR24, DHCR7, DIS3L2, DKC1, DLG3, DLG4, DNAJC12, DNM1, DNMT3A, DOCK7, DOLK, DONSON, DPAGT1, DPF2, DPM1, DPM2, DPM3, DVL1, DVL3, DYNC1H1, DYRK1A, EBP, EDC3, EED, EEF1A2, EHMT1, EIF2B5, EIF2S3, EIF3F, ELP2, EP300, EPB41L1, EXOSC3, EXOSC8, EXOSC9, EZH2, FANCB, FBXO31, FGD1, FLNA, FMN2, FMR1, FOXG1, FOXP1, FOXP2, FRMPD4, FTSJ1, GABRA1, GALT, GATAD2B, GCDH, GCH1, GDI1, GFAP, GK, GLI3, GNAI1, GNAO1, GNB1, GPAA1, GPC3, GPSM2, GRIA3, GRIK2, GRIN1, GRIN2A, GRIN2B, HCCS, HCFC1, HCN1, HDAC4, HDAC6, HDAC8, HEPACAM, HERC1, HIST1H1E, HIVEP2, HMGB3, HNRNPH2, HPRT1, HRAS, HSD17B10, HUWE1, IDS, IGBP1, IL1RAPL1, IMPA1, IQSEC2, ITPA, KANSL1, KAT6A, KAT6B, KATNB1, KCNA2, KCNB1, KCNQ2, KCNQ3, KCNQ5, KCNT1, KDM5C, KDM6A, KIF11, KIF14, KIF1A, KIF4A, KIF7, KIRREL3, KLHL15, KLHL7, KMT2A, KMT2D, KMT2E, KMT5B, KNL1, KPTN, KRAS, L1CAM, LAMB1, LAMP2, LAS1L, LINGO1, LINS1, LMNB1, LMNB2, LZTR1, MACF1, MAGT1, MAN1B1, MAOA, MAP11, MAP2K2, MBD5, MBOAT7, MBTPS2, MCPH1, MECP2, MED12, MED13, MED13L, MED23, MEF2C, METTL23, METTL5, MFSD2A, MGAT2, MICU1, MID1, MID2, MLC1, MOGS, MPDU1, MPI, MRAS, MSL3, MTM1, MTOR, MYT1L, NAA10, NAA15, NALCN, NCAPD2, NCAPD3, NCAPH, NDE1, NDP, NDST1, NDUFA1, NEXMIF, NFIB, NFIX, NGLY1, NHS, NIPBL, NLGN3, NLGN4X, NONO, NRAS, NRXN1, NSD1, NSDHL, NSUN2, NTNG1, NUP37, NUS1, NXF5, NXN, OCRL, OFD1, OGT, OPHN1, OTC, PACS1, PAFAH1B1, PAK3, PCBD1, PCDH11X, PCDH19, PCNT, PDHA1, PGAP1, PGAP2, PGAP3, PGK1, PGM1, PHC1, PHF6, PHF8, PIGA, PIGB, PIGC, PIGG, PIGH, PIGL, PIGM, PIGN, PIGO, PIGP, PIGQ, PIGS, PIGT, PIGU, PIGV, PIGW, PIGY, PIK3R2, PLP1, PMM2, PNKP, POGZ, PORCN, PPP1CB, PPP2CA, PPP2R1A, PPP2R5D, PPT1, PQBP1, PRPS1, PRSS12, PTCH1, PTCH2, PTCHD1, PTEN, PTPN11, PTS, PURA, PUS3, QDPR, RAB39B, RAB40AL, RAC1, RAD21, RAF1, RAI1, RARS2, RASA2, RBM10, RBMX, RELN, RFT1, RHEB, RIT1, RLIM, RNF113A, RNF135, ROR2, RPL10, RPL11, RPL15, RPL18, RPL26, RPL27, RPL35, RPL35A, RPL5, RPS10, RPS15A, RPS17, RPS19, RPS24, RPS26, RPS27, RPS28, RPS29, RPS6KA3, RPS7, RRAS, RUSC2, SASS6, SATB2, SCN1A, SCN2A, SCN8A, SCN9A, SEPSECS, SET, SETBP1, SETD2, SETD5, SHANK2, SHANK3, SHOC2, SIK1, SLC12A5, SLC13A5, SLC16A2, SLC18A2, SLC25A22, SLC25A46, SLC25A5, SLC35A1, SLC35A2, SLC35C1, SLC39A8, SLC6A17, SLC6A3, SLC6A8, SLC9A6, SMARCA2, SMARCA4, SMARCB1, SMARCC2, SMARCD1, SMARCE1, SMC1A, SMC3, SMPD4, SMS, SNX14, SON, SOS1, SOS2, SOX11, SOX3, SOX4, SOX5, SPR, SPTAN1, SRCAP, SRD5A3, SSR4, ST3GAL3, STAG1, STAG2, STIL, STT3A, STT3B, STXBP1, SUFU, SYN1, SYNGAP1, SYP, SZT2, TAF1, TAF13, TAF2, TBC1D23, TBC1D24, TBC1D7, TBCD, TBCK, TBL1XR1, TBR1, TCF4, TECR, TH, THOC2, TIMM8A, TLK2, TMCO1, TMEM165, TMEM199, TMLHE, TMTC3, TNIK, TOE1, TPH2, TRAPPC9, TRIO, TRIP12, TRMT1, TRRAP, TSC1, TSC2, TSEN15, TSEN2, TSEN34, TSEN54, TSPAN7, TSR2, TTI2, TUBA1A, TUBA8, TUBB, TUBB2A, TUBB2B, TUBB3, TUBG1, TUSC3, UBE2A, UBE3A, UPF3B, USP27X, USP9X, VPS13B, VPS51, VPS53, VRK1, WAC, WASHC4, WASHC5, WDFY3, WDR45, WDR62, WNT5A, WWOX, ZBTB11, ZBTB18, ZC3H14, ZC4H2, ZCCHC12, ZDHHC15, ZDHHC9, ZEB2, ZMYM3, ZMYND11, ZNF335, ZNF41, ZNF674, ZNF711, ZNF81
How to order

LATEST ARTICLES

Breast cancer is a type of cancer that originates in the breast cells. Genetic changes in the DNA of the healthy breast cells can lead to the formati...

Read more

Cardiovascular diseases affect the heart and blood vessels and are a leading cause of illness and death. Some are hereditary, and genetic testing can...

Read more

A recent study tracked molecular changes in 108 people over time, revealing that aging involves critical shifts around ages 44 and 60. These changes ...

Read more

In May 2024, the American Society of Clinical Oncology (ASCO) published new guidelines for germline genetic testing in patients with cancer (1). ...

Read more

Genetics as we know and understand it today has been shaped, over decades, by the work of many dedicated scientists around the world, and they all de...

Read more

A comprehensive single-cell transcriptomic atlas of 1.3 million cells from aged human brains reveals cellular pathways linked to Alzheimer’s diseas...

Read more

Infertility is a struggle for many individuals nowadays. According to the World Health Organization (WHO), 1 in 6 people experience infertility, show...

Read more

A recent study highlights promising outcomes for BRCA variant carriers with breast cancer undergoing breast-conserving therapy. Analyzing 172 women, ...

Read more

Epidermolysis bullosa (EB), sometimes called butterfly skin, is a group of rare skin diseases with a common symptom: fragile skin that tears and blis...

Read more

In the rapidly evolving field of human genetics diagnostics, laboratories face the challenge of keeping up with the latest advancements in technology...

Read more